Frontotemporal Dementia

Frontotemporal Dementia

News & Stories

Young boy in purple t-shirt sits smiling in the grass on a sunny day.
Health Lab

From 20 seizures a day to more time for play: How personalized epilepsy care helped young patient

Advanced genetic testing and a detailed diagnosis revealed infant’s rare epilepsy, leading to a non-conventional therapy.
Minding memory above a microphone on a blue background
Minding Memory

Giving Voice to Lived Experience in Dementia Research

In this episode, Lauren & Matt talk to Brenda Roberts and Steven Barbieri from the National Council of Dementia Minds. The National Council of Dementia Minds is the first national not-for-profit organization founded and governed by people living with dementia. Its work focuses on education, advocacy, peer support, and changing public perception of what it means to live with dementia. Brenda and Steven talk about the National Council of Dementia Minds, the importance of peer support and education for people living with dementia. They focus on how better understanding the lived experiences of people living with dementia can help shape research, policy, and advocacy.
David Diebold smiles as he rings the bell at the end of the HURT100.
Philanthropy News

Going the extra 100 miles

U-M Medical School student runs the HURT100 ultramarathon to raise funds for the Michigan Alzheimer's Disease Center and the Alzheimer's Association.
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory

Antipsychotic Use in Nursing Homes: Balancing Medication Safety, Policy, and Dementia Care

In this episode, Lauren Gerlach and Matt Davis speak with Theresa Shireman, PhD, Director of the Center for Gerontology and Healthcare Research and a Professor of Health Services, Policy and Practice and Epidemiology at the Brown University School of Public Health. Dr. Shireman’s research focuses on pharmaceutical policy, pharmacoepidemiology, health services research, and medication use among vulnerable populations. Dr. Shireman discusses her recent study, "Impact of Federal Antipsychotic Use Policy in Nursing Homes on New Diagnoses for Approved Indications in Dementia Residents," published in the Journal of the American Geriatrics Society. The study examines whether federal policies designed to reduce antipsychotic use in nursing homes were associated with increases in new diagnoses of conditions, such as schizophrenia, that exclude residents from publicly report antipsychotic quality measures. Using an interrupted time-series design, the researchers examined changes following the 2012 National Partnership to Improve Dementia Care and the 2015 addition of antipsychotic use to the Nursing home Five-Star Quality Rating System. They found that neither policy was associated with an increase in new exclusionary diagnossees, challenging concerns that nursing homes were increasingly assigning these diagnoses to circumvent restrictions on antipsychotic use. The conversation also explores the benefits and risks of antipsychotic medications for people living with dementia, including the potential for serious adverse effects such as sedation, falls, stroke, and increased mortality. Dr. Shireman discusses how public reporting and financial incentives can influence prescribing practices,the limitations of using a single quality measure to evaluate nursing home care, and the importance of balancing medication safety and residents’ individual needs. The discussion highlights the need for shared decision-making among clinicians, nursing home staff, residents, and families, as well as greater investment in staffing, resources, and nonpharmacological approaches to improve quality of life for people living with dementia. The transcript for this episode can be found here.
Minding memory above a microphone on a blue background
Minding Memory

Can Your Voice Reveal Early Signs of Alzheimer’s?

In this episode, Lauren & Matt speak with Neguine Rezaii, MD, an Assistant Professor of Neurology at Harvard Medical School and a Board-Certified Neuropsychiatrist at Mass General Hospital. Dr. Rezaii’s research focuses on using natural language processing and artificial intelligence to improve the detection and classification of neurodegenerative disorders. Dr. Rezaii talks about her recent study, “Voiceprints of Cognitive Impairment: Analyzing Digital Voice for Early Detection of Alzheimer’s and Related Dementias,” which explores how artificial intelligence can analyze short speech samples to identify subtle signs of cognitive impairment. The study used speech recordings from 120 individuals and found that features such as pauses, word choice and the specificity of language can help distinguish cognitive impairment and Alzheimer’s disease. The conversation also explores how a simple 30-second speech test could potentially be used in clinical settings to support earlier detection and monitoring of cognitive impairment, as well as the challenges and ethical considerations that come with using AI to analyze something as personal as a person’s voice.
Cole, wearing sunglasses and a purple Calming the Storm t-shirt with a rainbow, is seated on a blanket outdoors and holding a Mott teddy bear.
Philanthropy News

A pediatric epilepsy fundraiser that changes lives

Your support of Calming the Storm advances pediatric epilepsy research and patient care programs. There are many ways you can contribute to make a difference for so many children and families.